1例卡瑞利珠单抗致重度心肌炎不良反应及临床分析

免疫检查点抑制剂在临床的使用范围逐渐扩大,可明显延长患者生存期,但其独特的免疫相关不良反应也应该引起人们的重视。本文分析1例61岁晚期肺癌女性患者使用卡瑞利珠单抗(200 mg,ivgtt q2w)12天后,出现头晕并逐渐加重,考虑为PD-1抑制剂引起的免疫相关性肌炎累及心肌、伴横纹肌溶解的重叠综合征,予以激素冲击联合免疫球蛋白抗炎及其他对症治疗,但最终结局并未好转。

Clinical analysis of a case of severe myocarditis induced by camrelizumab

Immune checkpoint inhibitors are widely used in clinic and they can significantly prolong the survival of patients, but their unique immune-related adverse reactions should also be paid attention to. In this paper, we discussed a case of 61-year-old female patient with advanced lung cancer received camrelizumab (200 mg, ivgtt q2w) treatment. The patient appeared dizzy after 12 days of camrelizumab treatment, and it was gradually aggravated. It was considered to be immune-related myositis involving myocardium and rhabdomyolysis overlap syndrome caused by PD-1 inhibitor. The patient was given steroid therapy, immunoglobulin and other symptomatic treatment. Unfortunately, the condition of this patient was not improved after treatment.